Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases

Study Overview
=================
Brief Summary
-----------------
Suprachoroidal injection is a safe way for intraocular drug delivery. It was used to treat various retinal conditions.

Detailed Description
-----------------
Suprachoroidal triamcinolone acetonide injection is used to treat various retinal diseases, higher concentration of the injected material is found when the suprachoroidal space is used as an intraocular delivery pathway when compared to the conventional intravitreal pathway.

Official Title
-----------------
Suprachoroidal Triamcinolone Acetonide Injection in Two Chorioretinal Diseases: One Year Results

Conditions
-----------------
Central Serous Chorioretinopathy, Irvine-Gass Syndrome, Pars Planitis, Cystoid Macular Edema

Intervention / Treatment
-----------------
* Drug: Triamcinolone Acetonide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed as central serous chorioretinopathy and patients with cystoid macular edema due to irvine-gass syndrome after cataract surgery. Exclusion Criteria: other retinal diseases that may affect CMT and final visual outcome. Patients with dense corneal opacity.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Central serous chorioretinopathy group<br>Cases with central serous chorioretinopathy (CSR) that will be injected with suprachoroidal triamcinolone acetonide. | Drug: Triamcinolone Acetonide<br>* Suprachoroidal injection of triamcinolone acetonide<br>* Other names: Suprachoroidal triamcinolone acetonide injection (SCTA);|
| Experimental: Irvine-Gass Syndrome group<br>Cases with cystoid macular edema due to irvine-gass syndrome that will be injected with suprachoroidal triamcinolone acetonide | Drug: Triamcinolone Acetonide<br>* Suprachoroidal injection of triamcinolone acetonide<br>* Other names: Suprachoroidal triamcinolone acetonide injection (SCTA);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Central macular thickness | Changes in central macular thickness (CMT) measured in millimeters (mm) by optical coherence tomography (OCT) | Baseline and 12 months after injection. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best corrected visual acuity | Changes in best corrected visual acuity (BCVA) measured in logarithm of minimal angle of resolution (LogMAR) by chart projector. | Baseline and 12 months after injection. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Central serous chorioretinopathy, Cystoid macular edema